Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05963984 · ClinicalTrials.gov registry record · Phase 2
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants
A Phase 2 study, sponsored by Carrick Therapeutics Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT05963984 is a Phase 2 study that has completed, run by Carrick Therapeutics Limited. The registered enrollment target is 60 participants.
The verdict
NCT05963984, a Phase 2 study, has completed, sponsored by Carrick Therapeutics Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of samuraciclib in combination with fulvestrant versus fulvestrant alone in adult participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast cancer.
Interventions
- DRUG Fulvestrant
- DRUG Samuraciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-11-16 |
| Est. Completion | 2025-08-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05963984
The ClinicalTrials.gov registry entry for NCT05963984 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carrick Therapeutics Limited, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fulvestrant is the first listed.
NCT05963984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05963984 about?
NCT05963984 is a clinical study titled "A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants". The purpose of this study is to evaluate the safety and efficacy of samuraciclib in combination with fulvestrant versus fulvestrant alone in adult participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast cancer.
What is the current status of trial NCT05963984?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-11-16. Estimated completion is 2025-08-28.
What interventions are being tested in trial NCT05963984?
The interventions under investigation include: Fulvestrant (DRUG), Samuraciclib (DRUG).
Who is sponsoring clinical trial NCT05963984?
This trial is sponsored by Carrick Therapeutics Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.